Schizophrenia accounted for a 2.9% share of the global clinical trials within the Central Nervous System therapy area in 2020, registering a decrease of 1.4% when compared with the last ten-year average of 4.3% share, according to GlobalData.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Industry sponsored trials outnumber non-industry sponsored trials for Schizophrenia
Industry sponsored trials held a 56.4% share of all the clinical trials for Schizophrenia indication in 2020, registering an increase of 7.7% when compared with the ten-year average of 48.7%. Non-industry sponsored trials accounted for a 43.6% share in 2020, marking a decrease of 7.7% over the ten-year average of 51.3%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Top regions of industry sponsored Schizophrenia trials
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataAsia-Pacific was the top region for industry sponsored Schizophrenia trials, accounting for a 65.5% share in 2020, when compared with the five-year average of 46.0% and ten-year average of 41.5%.
North America was at the second position with a 32.7% share in 2020, over the five-year average of 39.3% and ten-year average of 44.7%, followed by Europe with a 14.5% share in 2020, as against five-year and ten-year averages of 31.7% and 36.3% respectively.
Middle East and Africa stood fourth with a 0.0% share in 2020, compared with the five-year average of 3.4% and ten-year average of 4.2%, followed by South and Central America with a 0.0% share in 2020, over five-year and ten-year averages of 3.5% and 5.5% respectively.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
China was the top country for industry sponsored Schizophrenia trials, accounting for a 43.6% share in 2020, as against the five-year average of 18.0% and ten-year average of 12.1%.
The US held a 32.7% share in 2020, over the five-year average of 38.9% and ten-year average of 43.7%, followed by India with a 12.7% share in 2020, compared with the five-year and ten-year averages of 14.7% and 13.5% respectively.
Japan held a 9.1% share in 2020, as against the five-year average of 6.0% and ten-year average of 8.5%.
Poland held a 7.3% share in 2020, over the five-year and ten-year averages of 6.2% and 6.4% respectively.
Top regions of non-industry sponsored Schizophrenia trials
Asia-Pacific was the top region for non-industry sponsored Schizophrenia trials, accounting for a 42.2% share in 2020 when compared with the five-year average of 43.1% and ten-year average of 38.4%.
Middle East and Africa was at the second position with a 26.7% share in 2020, over the five-year and ten-year averages of 18.6% and 20.0% respectively, followed by North America with a 17.8% share in 2020, as against the five-year average of 23.0% and ten-year average of 25.6%.
Europe stood at the fourth position with an 11.1% share in 2020, compared with the five-year average of 16.3% and ten-year average of 17.6%, followed by South and Central America with a 2.2% share in 2020, over the five-year and ten-year averages of 0.8% and 0.7% respectively.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
China was the top country for non-industry sponsored Schizophrenia trials, accounting for a 26.7% share in 2020, as against the five-year average of 22.4% and ten-year average of 14.8%.
Iran held a 26.7% share in 2020, over the five-year average of 15.6% and ten-year average of 15.9%, followed by US with a 17.8% share, compared with the five-year and ten-year averages of 19.8% and 23.1% respectively.
Japan held a 6.7% share in 2020, as against the five-year average of 4.8% and ten-year average of 8.2%.
Denmark held a 4.4% share in 2020, over the five-year average of 0.8% and ten-year average of 2.1%.
Phase I trials lead industry sponsored clinical trials for Schizophrenia in 2020
Phase I trials held a 64.5% share of industry sponsored clinical trials for Schizophrenia in 2020, over the five-year average of 59.4% and ten-year average of 53.6%.
Phase II trials held a 16.1% share in 2020, as against the five-year average of 15.0% and ten-year average of 13.9%. Phase IV trials held an 11.3% share in 2020, compared with the five-year and ten-year averages of 8.5% and 9.4% respectively.
Phase III trials held an 8.1% share in 2020, over the five-year average of 17.1% and ten-year average of 23.1%.
Phase II trials lead non-industry sponsored clinical trials for Schizophrenia in 2020
Phase II trials held a 47.9% share of non-industry sponsored clinical trials for Schizophrenia in 2020, over the five-year average of 38.9% and ten-year average of 44.0%.
Phase III trials held a 29.2% share in 2020, as against the five-year average of 18.7% and ten-year average of 15.6%. Phase IV trials held a 12.5% share, compared with the five-year and ten-year averages of 30.3% and 30.2% respectively.
Phase I trials held a 10.4% share in 2020, over the five-year average of 12.1% and ten-year average of 10.1%.
Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.
